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18-Glycyrrhetinic Acid Triggers Curative Th1 Response and
Nitric Oxide Up-Regulation in Experimental Visceral
Leishmaniasis Associated with the Activation of NF-B1
Anindita Ukil,2 Aruna Biswas,2 Tapasi Das, and Pijush K. Das3
The efficacy of 18-glycyrrhetinic acid (GRA), a pentacyclic triterpene belonging to the -amyrin series of plant origin, was
evaluated in experimental visceral leishmaniasis. GRA is reported to have antitumor and immunoregulatory activities, which may
be attributable in part to the induction of NO. Indeed, an 11-fold increase in NO production was observed with 20 M GRA in
mouse peritoneal macrophages infected with Leishmania donovani promastigotes. In addition to having appreciable inhibitory
effects on amastigote multiplication within macrophages (IC50, 4.6 g/ml), complete elimination of liver and spleen parasite
burden was achieved by GRA at a dose of 50 mg/kg/day, given three times, 5 days apart, in a 45-day mouse model of visceral
leishmaniasis. GRA treatment resulted in reduced levels of IL-10 and IL-4, but increased levels of IL-12, IFN-, TNF-, and
inducible NO synthase, reflecting a switch of CD4 differentiation from Th2 to Th1. This treatment is likely to activate immunity,
thereby imparting resistance to reinfection. GRA induced NF-B migration into the nucleus of parasite-infected cells and caused
a diminishing presence of IB in the cytoplasm. The lower level of cytoplasmic IB in GRA-treated cells resulted from increased
phosphorylation of IB and higher activity of IB kinase (IKK). Additional experiments demonstrated that GRA does not
directly affect IKK activity. These results suggest that GRA exerts its effects at some level upstream of IKK in the signaling
pathway and induces the production of proinflammatory mediators through a mechanism that, at least in part, involves induction
of NF-B activation. The Journal of Immunology, 2005, 175: 1161–1169.
V isceral leishmaniasis is a fatal and chronic protozoan in-fection caused by Leishmania donovani, an obligate in-tramacrophage parasite (1). Currently available antil-
eishmanial drugs are few, and the regimen used is lengthy.
Moreover, they produce serious side effects, and the refractory
cases are a problem (2). The disease is associated with immuno-
logical dysfunctions of T cells, NK cells, and macrophages (3–5).
Studies performed on mice infected with Leishmania demonstrated
that host defense against this infection depends on IL-12-driven
expansion of the Th1 subset, with production of cytokines such as
IFN- that activate macrophages for parasite killing through the
release of NO (6). NO, which mediates many of the nonspecific
cytotoxic and inflammatory responses of macrophages after infec-
tion by pathogens, is generated after the up-regulation of expres-
sion of the inducible form of NO synthase (iNOS).4 Similarly, the
biological activity of IL-12 (a heterodimeric cytokine comprising
p35 and p40 subunits), which is the key cytokine driving Th1 cell
development (7, 8), is regulated by the induction of the p40 subunit
(9). The expression of these immunomodulatory proteins appears
to be regulated primarily at the level of transcription; indeed,
NF-B activation has been shown to be a key factor in the regu-
lation of induction in both cases (10–12). The NF-B family is
comprised of five members: NF-B1 (p50/p105 (p50 precursor)),
NF-B2 (p52/p100 (p52 precursor)), Rel A (p65), Rel B (p68), and
c-Rel (p75) (13). Although most members are capable of main-
taining homo- and heterodimeric complexes, the most prevalent
activated form of NF-B is the heterodimer p50-p65, which pos-
sesses the transactivity domains necessary for gene regulation (11,
14, 15). In most cells, NF-B is present as a latent, inactive, IB-
bound complex in the cytoplasm, but upon activation by extracel-
lular stimuli or other factors, NF-B rapidly translocates to the
nucleus and activates gene expression (12). The exact molecular
mechanism by which various extracellular stimuli lead to the ac-
tivation of NF-B is not well understood. However, most signals
induce the activity of a large multisubunit protein kinase, called
IB kinase (IKK). Activation of the IKK complex leads to specific
IB phosphorylation/degradation and subsequent release of NF-
B, which then translocates to the nucleus and activates transcrip-
tion of multiple B-dependent genes, including iNOS and Th1
cytokines. The ability to interfere with the degradation of IB is
one of the strategies used by some pathogens to inhibit the action
of NF-B. Although the exact mechanism is still unclear, it has
been shown that L. donovani promastigotes are able to prevent
phosphorylation and subsequent degradation of IB in normal
bone marrow-derived macrophages, which effectively shuts down
the NF-B-dependent expression of proinflammatory cytokines
(16). Thus, the promastigotes successfully avoid activating the
macrophages for the production of NO. Activation of the NF-B
pathway may, therefore, prove a promising approach for the ther-
apy of visceral leishmaniasis.
Despite the tremendous progress in synthetic chemistry, medic-
inal plants continue to play an important role as a source of bio-
logically active agents (17). Of late, a large number of dietary
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components have been evaluated as potential chemopreventative
agents (18). The root of the medicinal plant licorice (Glycyrrhizza
glabra L) is widely used as a flavoring and sweetening agent in
food products. Its major water-soluble component, 18-glycyrrhe-
tinic acid (GRA), a pentacyclic triterpene derivative of the
-amyrin type, has long been used in traditional or folk medicine
of the east. It is known to exhibit a variety of pharmacological
effects, including antiulcerative, antihepatotoxic, and immuno-
regulatory activities (19–21). GRA also produces a wide variety of
antitumor activities, including inhibition of tumorigenesis (22) and
tumor production (23) and the induction of tumor cell differenti-
ation (24). Immunomodulatory and antitumor effects of GRA may
be mediated by the released NO from macrophages; recent reports
have demonstrated that GRA stimulates NO and is able to up-
regulate iNOS through NF-B transactivation in resting macro-
phages (25). However, the mechanism of action for GRA is not
well understood.
Because the L-arginine-NO pathway is implicated in the mac-
rophage-induced killing of Leishmania spp., we tested the capa-
bility of GRA to establish and maintain a Th1 curative response for
visceral leishmaniasis and to redirect the Th2 response associated
with disease progression. Our investigation was also aimed toward
understanding the molecular mechanism of GRA action on the
IB/NF-B signaling pathway, which may be associated with sup-
pressing the functional differentiation of Th2-type CD4 T cells
and, in turn, augmenting Th1 response. In this study we present
data demonstrating that GRA can induce the generation of NO and
proinflammatory cytokines, resulting in the abrogation of parasite
infection. Our results also demonstrate that GRA induces IB
phosphorylation and degradation by activating IKK in macro-
phages, leading to enhancement of NF-B DNA binding activity
and translocation of NF-B p65 into the nucleus.
Materials and Methods
Parasite, NO production, and in vitro killing assay
L. donovani (MHOM/IN/1983/AG83) parasites were cultured as promas-
tigotes in medium 199 (Invitrogen Life Technologies) with Hanks’ salt
containing HEPES (12 mM), L-glutamine (20 mM), 10% heat-inactivated
FCS, 50 U/ml penicillin, and 50 g/ml streptomycin. Adherent peritoneal
macrophages (BALB/c) or the murine macrophage cell line RAW 264.7
were cultured at 37°C with 5% CO2 in RPMI 1640 (Invitrogen Life Tech-
nologies) supplemented with 10% FCS, penicillin (100 U/ml), and strep-
tomycin (100 g/ml). Nitrite production was determined in macrophage
culture medium by the Griess reaction, as previously described (26). Cell
viability was assessed using an MTT-based colorimetric assay kit (Roche)
according to the manufacturer’s instructions. For in vitro killing assays,
adherent macrophages on glass coverslips (18 mm2; 5 105 macrophages/
coverslip) in 0.5 ml of RPMI 1640/10% FCS were infected with promas-
tigotes at a ratio of 10 parasites/macrophage. Infection was allowed to
proceed for 4 h, and the cells were washed to remove excess parasites, as
previously described (26). Cells were then resuspended in medium with
GRA for various time periods at 37°C. Intracellular parasite numbers were
determined by staining with Giemsa.
Infections and GRA treatment
For experimental infections, BALB/c mice (20–25 g) were injected with
107 promastigotes through the tail vain, and for reinfection, the same num-
ber of promastigotes was injected 45 days after the first infection. GRA
(Sigma-Aldrich) was given i.p. in various doses on days 10, 15, and 20
after infection. Spleen and liver were removed from 45-day infected mice,
and multiple impression smears were prepared and stained with Giemsa.
Spleen or liver parasite burdens, expressed as Leishman-Donovan units
(LDU), were calculated as the number of parasites per 1000 nucleated
cells  organ weight (in grams) (27).
Analysis of cytokines
Every 15 days after infection up to 45 days, single-cell suspensions were
prepared using splenocytes from infected mice as described previously
(28). Cells were cultured in 96-well tissue culture plates at 4 106 cells/ml
and stimulated with 20 g/ml soluble leishmanial Ag (SLA) for 48 h. SLA
was prepared as previously described (26). Supernatants were assayed di-
rectly using an ELISA kit (BD Pharmingen) for IL-12, IFN-, TNF-,
IL-10, and IL-4, as recommended by the manufacturer. mRNA profiles for
these cytokines along with -actin as the internal control were analyzed by
RT-PCR. RT of 1 g of RNA was performed according to the manufac-
turer’s protocol for the Superscript One-Step RT-PCR system (Invitrogen
Life Technologies). Oligonucleotide primers for these cytokines were se-
lected from published cDNA sequences. After the appropriate number of
PCR cycles, the amplified DNA was separated by 2% agarose gel electro-
phoresis and visualized by ethidium bromide staining.
Inducible NOS expression by RT-PCR and immunoblot analysis
RT-PCR was performed to determine the mRNA profile for iNOS along
with -actin as an internal control. For immunoblot analysis, 20 g of
whole cell extracts were resolved by SDS-PAGE, electroblotted to nitro-
cellulose membrane, and probed with murine anti-iNOS Ab (BD Trans-
duction Laboratories). After extensive washing, the Ag-Ab complexes
were detected using the ECL kit (Amersham Biosciences) with HRP-con-
jugated anti-rabbit IgG (1/2000 dilution).
Preparation of nuclear and cytoplasmic extracts
The nuclear extracts were prepared from normal and infected macrophages
in the presence or the absence of GRA as described by Yaron et al. (29).
Briefly, sedimented cells were resuspended in hypotonic buffer (10 mM
HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.2 mM PMSF, and 0.5
mM DTT) and allowed to swell on ice for 10 min. Cells were homogenized
in a Dounce homogenizer (Kontes). The nuclei were separated by spinning
at 3300 g for 5 min at 4°C. The supernatant was used as the cytoplasmic
extract. The nuclear pellet was extracted in nuclear extraction buffer (20
mM HEPES (pH 7.9), 0.4 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25%
glycerol, 0.5 mM PMSF, and 0.5 mM DTT) for 30 min on ice and cen-
trifuged at 12,000  g for 30 min. The supernatant was used as nuclear
extract.
EMSA
For nuclear mobility shift assay, each 10 g of nuclear extracts were pre-
incubated with 1 g of poly(dI-dC) in a binding buffer (25 mM HEPES
(pH 7.9), 0.5 mM EDTA, 0.5 mM DTT, 1% Nonidet P-40, 5% glycerol,
and 50 mM NaCl) for 10 min at room temperature. As a control, a 100-fold
molar excess of unlabeled NF-B competitor oligonucleotide was added.
After preincubation, 0.5 ng of 32P end-labeled NF-B oligonucleotide
probe (5-CGGGGACTTTCCGCTGGGGACTTTCCGCTTGAGCT-3)
was added to the reaction mixture and incubated for 30 min. The DNA-
protein complex was then electrophoresed on 4.5% nondenaturing poly-
acrylamide gels in 0.5 TBE buffer (50 mM Tris, 50 mM borate, and 1
mM EDTA) and analyzed by autoradiography. For supershift assay, the
nuclear extracts from GRA-treated cells were incubated with anti-p65 or
anti-p50 polyclonal Ab (Santa Cruz Biotechnology) for 30 min at 25°C and
analyzed by EMSA in the presence of all components of the binding re-
action described above. As controls, the nuclear extracts were also treated
with normal rabbit IgG.
Western blot analysis
For detection of p65 translocation, normal and infected macrophages were
treated with GRA. The nuclear extracts were prepared as described above,
and the protein concentrations were measured with a Bio-Rad protein as-
say. The nuclear extract (30 g) was resolved by SDS-PAGE, then elec-
trotransferred to nitrocellulose membrane. The membranes were incubated
with p65 Ab, washed, incubated further with HRP-conjugated anti-rabbit
IgG (1/2000 dilution), and detected using an ECL detection kit. For IB
phosphorylation studies, GRA-treated normal and infected macrophages
were lysed in lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1%
Nonidet P-40, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 5
mM iodoacetamide, and 2 mM PMSF), and the protein concentrations in
cleared supernatants were measured using a Bio-Rad protein assay. The
supernatant (lysates) containing equal amount of total protein (30 g) was
resolved by SDS-PAGE and electrotransferred from gel to nitrocellulose
membranes. The membranes were incubated with rabbit anti-
phospho-IB Ab (1/500 dilution), additionally incubated with HRP-con-
jugated anti-rabbit IgG, and detected by ECL detection system (Amersham
Biosciences) according to the manufacturer’s instructions. To demonstrate
the effect of GRA on IB degradation, cytoplasmic extracts after resolu-
tion by SDS-PAGE were probed with anti-IB Ab (1/500 dilution) and
detected using the ECL detection system as described above.
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IKK assay
IKK activity was measured as described by Philip and Kundu (30). GRA-
treated normal and infected macrophages were lysed in cold kinase assay
lysis buffer (20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1 mM EDTA, 1
mM EGTA, 10 mM -glycerophosphate, 10 mM sodium fluoride, 10 mM
p-nitrophenylphosphate (pNPP), 300 M Na3VO4, 1 mM benzamidine, 2
M PMSF, 10 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin, 1
mM DTT, and 0.25% Nonidet P-40). The supernatant was obtained by
centrifugation at 12,000 g for 10 min at 4°C. Protein concentrations were
measured using a Bio-Rad protein assay. The cell lysates (300 g) were
immunoprecipitated with anti-IKK/IKK Ab in immunoprecipitation
buffer (40 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 10 mM -glycerophosphate, 10 mM sodium fluoride, 10 mM
pNPP, 300 M Na3VO4, 1 mM benzamidine, 2 M PMSF, 10 g/ml
aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin, 1 mM DTT, and 0.1%
Nonidet P-40). Immunoprecipitated samples were incubated with recom-
binant IB (4 g) in kinase buffer (20 mM HEPES (pH 7.7), 2 mM
MgCl2, 10 M ATP, 3 Ci of [-32P]ATP, 10 mM -glycerophosphate, 10
mM sodium fluoride, 10 mM pNPP, 300 M Na3VO4, 1 mM benzamidine,
2 M PMSF, 10 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin,
and 1 mM DTT) at 30°C for 1 h. The kinase reaction was stopped by
addition of SDS-sample buffer. The sample was resolved by SDS-PAGE,
dried, and autoradiographed. To determine the total amounts of IKK and
IKK in each sample, 30 g of the whole cell extract protein was subjected
to SDS-PAGE and analyzed by Western blot using anti-IKK and
IKK Ab.
Statistical analysis
The significance of the data was evaluated using a two-tailed t test.
Results
Effect of GRA on nitrite production
The generation of NO is an important host defense mechanism,
including antileishmanial protection. Because GRA might act as an
immunomodulator through NO production, we first investigated
the ability of GRA to up-regulate NO in L. donovani-infected mac-
rophages. As shown in Fig. 1A, GRA could up-regulate NO pro-
duction in peritoneal macrophages in a concentration-dependent
manner. The effect was maximal with a concentration of 20 M
after incubation for 24 h. To demonstrate that the effect observed
was related to the L-arginine-NOS pathway, we used the specific
NOS inhibitor, NG-monomethyl-L-arginine (NMMA). The addi-
tion of NMMA almost completely abolished nitrite production.
GRA exhibited no cytotoxicity at 20 M, although there was some
effect at higher concentrations (30 M). GRA-induced up-reg-
ulation was observed even in L. donovani-infected macrophages,
which exhibited an 11-fold increase in NO production after GRA
treatment (20 M for 24 h) compared with untreated cells (Fig.
1B). Preincubation of GRA with polymyxin B, an LPS inhibitor,
did not alter NO production, suggesting that the up-regulation of
NO by GRA in peritoneal macrophages is not due to LPS con-
tamination. This is confirmed by the observation that GRA could
induce comparable NO-generating ability in a bone marrow-de-
rived, LPS nonresponder, macrophage cell line (10ScNCr/23 from
mouse strain C57BL; American Type Culture Collection; Fig. 1B).
The level of nitrite produced by various regimens is also consistent
with the expression of iNOS mRNA, which, after isolation of total
RNA, was subjected to RT-PCR analysis (Fig. 1C).
In vitro and in vivo antileishmanial effects
Because GRA could up-regulate NO production, which is the most
effective antileishmanial mechanism, we checked the efficacy of
GRA on intracellular growth of L. donovani. Fig. 2A shows that
the in vitro effect of GRA on amastigote multiplication within
macrophages was dependent on both the concentration of the drug
and the duration of treatment. For each concentration of drug, the
inhibitory effect was found to be directly proportional to the du-
ration of treatment up to 24 h. No additional increase in antileish-
manial activity was achieved by increasing the treatment time to
48 h. The IC50 for 24-h treatment of GRA was 4.6 g/ml. To
ascertain the involvement of NO in the inhibition of intracellular
parasite growth, the infection index was measured in the presence
FIGURE 1. Effect of GRA on NO
production. A, Peritoneal macro-
phages (106 cells/ml) were treated
with various concentrations of GRA,
either alone or in the presence of
NMMA (2.5 M), for 24 h at 37°C.
Cell viability was assessed by an
MTT assay. B, Macrophages (106
cells/ml) were incubated with L. do-
novani (macrophage:parasite ratio,
1:10), GRA (20 M), GRA plus L.
donovani, LPS (1 g/ml), LPS plus
polymyxin B preincubation (10 U/ml
for 2 h), and GRA plus polymyxin B
preincubation. LPS nonresponder
macrophages (10ScNCr/23 from
mouse strain C57BL; 106 cells/ml)
were incubated with GRA (20 M)
and LPS (1 g/ml). Each bar shows
the mean  SD of three independent
experiments. C, The nature of iNOS
expression was determined by RT-
PCR in macrophages treated with L. do-
novani (lane 2), GRA (lane 3), GRA
plus L. donovani (lane 4), LPS (lane 5),
and GRA plus NMMA (lane 6). Lane 1
represents untreated macrophages.
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of a specific NOS inhibitor, NMMA. Increased leishmaniacidal
activity induced by GRA in infected macrophages was almost to-
tally abrogated by treatment with NMMA, suggesting that the an-
tileishmanial activity of GRA may be correlated with increased
production of NO. The potent in vitro antileishmanial activity of
GRA in the absence of obvious cytotoxicity on macrophage host
cells forms the basis for evaluating its efficacy in a murine model
of visceral leishmaniasis. The dose titration experiment assessed
the efficacy of GRA against established (10-day) infections with a
dose range of 1–100 mg/kg/day, given three times, 5 days apart.
The infection was allowed to proceed for 45 days, after which the
animals were killed, and antileishmanial potency was assessed in
terms of parasite burden in liver and spleen. During the experi-
ment, no marked effect on body weight was noted in any of the
experimental groups. In the placebo-treated infected controls, a
high burden of amastigotes was present in liver (3981 385 LDU)
and spleen (316  28 LDU). At a lower dose of GRA (1 mg/kg/
day), there was almost no control of infection (2 and 5% reductions
in liver and spleen, respectively), but a dose-related inhibition was
noted at higher doses, and at 50 mg/kg/day the inhibition was
almost complete, with greatly reduced levels of liver and spleen
parasite burden (Fig. 3A). Complete clearance of parasitemia was
also noticed when progression of visceral leishmaniasis was fol-
lowed in the presence of 50 mg/kg/day GRA administered on days
10, 15, and 20 (Fig. 3B). The organs of the treated animals did not
show the presence of any viable transformed promastigotes when
their homogenates were cultured for 2 wk, as described previously
(26). The results suggest that 50 mg/kg/day might be regarded as
the lowest active dose of GRA for curative treatment 10 days after
infection.
That the GRA therapy might also have effected a protective
immunity was indicated by a reinfection experiment. Reinfection
of animals after 45 days resulted in only a slight and transient
increase in organ parasite burden (Fig. 3C). To ascertain whether
GRA-treated mice also control the infection by an NO-dependent
mechanism, NMMA (50 mM) was administered 1 wk after rein-
fection. Within 3–4 days of NMMA administration, the organ par-
asite burden started to increase. The infection was under control
again after NMMA was withdrawn (Fig. 3C).
Effect of GRA on cytokine production
To evaluate the type of immunological response in L. donovani-
infected mice after GRA treatment, mRNA transcription levels for
IL-10, IL-4, IL-12 p40, IFN-, and TNF- were determined on
isolated spleen cells every 15 days after infection. The results
clearly demonstrated a high level of IL-10 and some IL-4 expres-
sion in infected untreated controls and a low expression level of
transcripts for IL-12, IFN-, and TNF- (Fig. 4A). In contrast, a
high level of IL-12, IFN-, and TNF- expression and a low level
of IL-10 and IL-4 expression were detected in infected GRA-
treated cases (Fig. 4B). The differential cytokine expression was
found to peak on day 30 after infection. Inducible NOS was also
found to be up-regulated in infected GRA-treated cells (Fig. 4C).
For additional confirmation, cytokine production was assessed in
FIGURE 2. Effects of concentration and duration of
treatment of GRA on amastigote proliferation within
peritoneal macrophages. A, Macrophages were infected
with L. donovani promastigotes (cell:parasite ratio,
1:10), and noningested promastigotes were removed. In-
fected macrophages were treated with various concen-
trations of GRA for different time periods and washed;
after culture for a total of 48 h, the number of parasites
inside macrophages was counted. In one set of experi-
ments, NMMA (2.5 M) was used along with GRA for
24 h. B, Growth rate of L. donovani amastigotes within
macrophages in the absence of GRA. The data represent
the mean  SD of three independent determinations.
FIGURE 3. Effect of GRA treatment on visceral infection in BALB/c mice. A, Various doses of GRA ranging from 1 to 100 mg/kg/day were given i.p.
on days 10, 15, and 20 after infection. The parasite burdens in liver and spleen were then determined at 45 days after infection. B, The course of visceral
infection was followed in BALB/c mice that had received three i.p. injections of GRA (50 mg/kg/day) on days 10, 15, and 20 after infection vs untreated
controls. C, The course of visceral reinfection was studied by i.v. administration of 1  107 L. donovani promastigotes into naive, age-matched BALB/c
mice and cured (50 mg/kg/day GRA-treated) mice. In one group of cured mice, NMMA (50 mM) was given in the drinking water 1 wk after reinfection
for 2 wk. Determining liver and spleen parasite burdens, expressed as log10LDU, monitored the progression of infection in all the cases. Results are from
three experiments and indicate the mean  SD for five to seven mice at each time point.
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spleen cells of GRA-treated infected animals at the protein level by
ELISA, which showed significantly more IL-12 p40, IFN-, and
TNF- than those from untreated infected controls (Fig. 5). These
results not only support the balance of Th1/Th2 cytokines in the
predominant profile of disease progression and resolution in leish-
maniasis, but also show the potential of GRA as a proper effector
molecule, which might induce protective responses. It should be
mentioned that the antileishmanial efficacy of conventional anti-
mony chemotherapy also required host T cells and an intact Th1
cell-type response with IL-12 and IFN- secretion (31). To deter-
mine whether up-regulation of Th1 cytokines by GRA is the mech-
anism by which GRA up-regulates iNOS in vivo, we applied 200
g of various anti-cytokine mAbs (Genzyme) along with GRA
(i.e., on days 10, 15, and 20) to L. donovani-infected mice. The
anti-cytokine mAbs reactive against IFN-, IL-12, or TNF-
greatly reduced GRA-mediated splenocyte iNOS induction at both
mRNA and protein levels, whereas splenocyte iNOS in mice
treated with GRA plus control Abs was similar to that in mice
treated with GRA alone (Fig. 4, C and D). Neutralizing mAbs to
other cytokines, such as IL-6, also had little effect on GRA-medi-
ated iNOS induction. The therapeutic effect of GRA, therefore,
may be attributed to the up-regulation of NO resulting from the
direct effect of GRA as well as through activation by Th1
cytokines.
Effect of GRA on NF-B DNA binding and activation
Because iNOS and many proinflammatory gene expressions are
regulated by NF-B, the effects of GRA on NF-B binding activity
were examined by EMSA in the nuclear protein extracts of RAW
264.7 cells (Fig. 6). GRA (20 M) treatment caused greatly in-
creased NF-B binding activity (lane 4) compared with that in
untreated cells (lane 1). Significantly, GRA treatment also resulted
FIGURE 4. A time-course pattern of cytokine expression in L. donovani-infected mice. RT-PCR analysis was performed for the expression of IL-10,
IL-4, IFN-, IL-12p40, and TNF- mRNA by splenocytes of infected (A) and GRA-treated (50 mg/kg; on days 10, 15, and 20 after infection; B) mice.
RT-PCR products were visualized by ethidium bromide staining. RNA samples were obtained from five mice in each group. Results are representative of
three separate samples. -Actin expression levels were used as controls for RNA content and integrity. Semiquantitative analysis of mRNA expression by
densitometry is shown in the extreme left and right panels (A1 and B1). Inducible NOS expression by RT-PCR (C) and Western blot (D) in splenocytes
of L. donovani-infected mice treated with GRA (50 mg/kg; on days 10, 15, and 20 after infection) and GRA along with various anti-cytokine mAbs (200
g/mouse; on days 10, 15, and 20 after infection) is shown. Control infected mice received normal mouse IgG (200 g) along with GRA. Band intensities
were analyzed by densitometry (C1 and D1).
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in marked induction of NF-B binding in L. donovani-infected
macrophages (lane 5), although L. donovani infection caused a
down-regulation of NF-B activation in naive macrophages (lane
3). Densitometric quantification of the NF-B-specific bands in-
dicated that there was a 3.3-fold increase in DNA binding in GRA-
treated infected cells compared with untreated infected cells. The
specificity of binding was confirmed by incubating the nuclear
extract with a 100-fold excess of unlabeled oligonucleotide, which
resulted in complete displacement of the NF-B-specific band
(lane 6). To further ascertain the authenticity of the NF-B band in
GRA-treated cells (Fig. 5B), nuclear extracts were incubated with
anti-p65, anti-p50 Ab, or both before analysis by EMSA. A shift of
the NF-B specific band to higher m.w. when the nuclear extracts
were treated with anti-p65 (lane 5), anti-p50 (lane 4), or both Abs
(lane 6) suggested that the GRA-activated complex consisted of
p65 and p50 subunits. Normal rabbit IgG, as a control, had no
effect on NF-B mobility (lane 3).
Effect of GRA on the translocation of p65
To determine the effects of GRA on the migration of p65 into the
nucleus, Western blot analysis of nuclear protein fractions was
conducted. As shown in Fig. 7A, GRA induced p65 translocation
into the nucleus in a time-dependent manner. Gradual accumula-
tion of p65 in the nuclear protein fraction of GRA-treated cells
started after 30 min and continued up to 120 min. Exposure of L.
donovani-infected macrophages to GRA also caused nuclear trans-
location of p65 within 30 min of addition of GRA. In contrast, in
untreated infected cells, most of the p65 was localized in cytosol
up to 120 min.
Role of GRA in IB phosphorylation
As a necessary prerequisite, for NF-B translocation to the nu-
cleus, cytoplasmic IB must be phosphorylated, ubiquitinated,
and degraded. To ascertain the effects of GRA on this event, nor-
mal and infected cells were treated with GRA (20 M) for 0–120
min and lysed. The lysates containing an equal amount of total
proteins were resolved by SDS-PAGE, and levels of phosphory-
lated IB were detected by Western blot analysis using anti-
phospho IB Ab. Preincubation of both normal and infected cells
with GRA markedly induced the phosphorylated IB signal as
early as 10 min, and it had almost disappeared after 60 min (Fig.
7B). In untreated infected cells, no IB phosphorylation was ob-
served. To gain insight into the phosphorylation-mediated degra-
dation of IB, a Western blot analysis was performed with GRA-
treated normal and infected cells using anti-IB Ab. With GRA
treatment, normal cells exhibited a rapid disappearance of cytoso-
lic IB during the first 60 min; after that, IB reappeared, pos-
sibly caused by NF-B, within 120 min (Fig. 7C). GRA-treated
infected cells followed the same pattern. Untreated infected cells
did not exhibit any transient change in cytoplasmic IB. The
bands were quantified by densitometry, and the fold changes com-
pared with the control were calculated.
Effect of GRA on IKK
Because IB is phosphorylated by the IKK multiprotein com-
plex, the effect of GRA on the status of intrinsic cellular IKK
activation was determined. Accordingly, normal or L. donovani-
infected macrophages were treated with GRA for 1 h. Cells were
lysed and immunoprecipitated with anti-IKK and IKK Ab. The
immunoprecipitated samples were used for kinase assay with re-
combinant IB as substrate. The radiolabeled, phosphorylated
IB-specific band was detected in GRA-treated cells, demon-
strating that GRA induced IKK activity in both normal and in-
fected cells (Fig. 8A, lanes 2 and 4). In contrast, IKK activity was
negligible in the normal untreated as well as infected untreated
FIGURE 6. Effect of GRA treatment on activation of NF-B in RAW
264.7 cells. A, Labeled NF-B probe was incubated with nuclear extracts
from normal and infected cells treated in the presence or the absence of
GRA (20 M) at 37°C for 3 h, and EMSA was performed. Normal mac-
rophages stimulated with LPS (1 g/ml) served as a positive control. The
specificity of binding was determined by adding to nuclear extracts from
GRA-treated normal cells a 100-fold molar excess of unlabeled NF-B
oligonucleotide. The bands were analyzed densitometrically, and fold
changes are indicated. B, For supershift assay, nuclear extracts from GRA-
treated cells were incubated with anti-p65, anti-p50, or both Abs for 30 min
before EMSA. Normal rabbit IgG was used as a control. The results are
representative of one of three separate experiments.
FIGURE 5. A time-course pattern of cytokine levels
in L. donovani-infected (A) and GRA-treated (50 mg/kg;
on days 10, 15, and 20 after infection; B) mice. Spleen
cells were isolated on the indicated days after infection,
plated aseptically (4  106 cells/ml), and stimulated
with SLA (20 g/ml) for 72 h. Ongoing cytokine pro-
duction was determined by ELISA. Results represent
the mean  SD of three mice per group studied
independently.
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macrophages (lanes 1 and 3). Western blot analysis with whole
cell lysates using anti-IKK and IKK Ab (Fig. 8A) showed iden-
tical levels of expression of IKK, suggesting that IKK was equally
expressed in cells with different treatments. To ascertain whether
GRA had any direct effect on IKK, it was immunoprecipitated
from normal macrophages, and GRA was added at the initiation of
the assay for IKK activity. The activity of IKK was unaltered by
the presence of GRA (Fig. 8B), suggesting that GRA exerts its
effect by stimulating upstream signaling pathways that activate
IKK, rather than by directly activating IKK activity.
Discussion
The use of biologically active natural products is becoming an
increasingly attractive approach for the treatment of various dis-
eases as an alternative to traditional medicine. However, limited
scientific evidence regarding the effectiveness of these natural de-
rivatives in conjunction with a lack of mechanistic understanding
have prevented their incorporation into the mainstream of medical
care. The present study has demonstrated that BALB/c mice with
visceral leishmaniasis may be completely cured of their parasite
burden by GRA, a relatively nontoxic, naturally occurring triter-
penoid, found in the licorice plant (Glycyrrhiza glabra), with a
number of medicinal properties. Even though BALB/c mice differ
from symptomatic human subjects with L. donovani infection in
that the infection is chronic, but not fatal, there is no evidence of
wasting, and the parasite burden decreases during the course of
infection, it serves as a good experimental model for the disease.
GRA is an immunomodulatory and antiproliferative triterpene that
has been shown to induce the production of NO and proinflam-
matory cytokines such as IL-12 (25, 32). The killing of intracel-
lular Leishmania parasites by GRA correlated with the induction
of the NOS pathway, because it correlated with the generation of
nitrogen derivative production and was abrogated in the presence
of NMMA, a competitive inhibitor of the NOS pathway. That the
mice treated with GRA were indeed cured was indicated by the
complete suppression of liver and spleen parasite burdens. More-
over, this therapy was effective in mice with ongoing infections in
which a disease-progressive Th2 response had been established.
After treatment and the resulting resolution of parasitism, the cy-
tokine profile in these mice indicated a switch to a protective Th1
pattern associated with up-regulation of NO. Because NF-B, the
Rel family of inducible transcription factors, plays a central role in
the evolution of inflammation through the regulation of genes es-
sentially involved in encoding proinflammatory cytokines and in-
flammatory mediators such as NO, the molecular mechanism of
GRA action on the IB/NF-B signaling pattern was determined
in parasite-infected macrophages. Our results demonstrate that
GRA can induce NF-B activation, which was suppressed by L.
donovani infection. GRA induced NF-B activation through the
induction of IB phosphorylation by stimulating the signal lead-
ing to IKK activation without directly interfering with IKK. This
ultimately caused the degradation of IB and the translocation of
NF-B in the nucleus with the possible transcriptional activation
of iNOS and proinflammatory cytokines. It is also possible that
GRA may act directly on T cells to induce NF-B activation. Re-
cently, NF-B activation within T cells has been implicated in the
Th1 response, independently of the role for this transcription factor
in APC production of IL-12 (33). Furthermore, NF-B induction is
required not only for clonal expansion, but also for full differen-
tiation and substantial IFN- production by each committed T cell.
Although GRA exhibited potent in vitro activity against intracel-
lular L. donovani amastigotes (IC50, 4.3 g/ml), it is devoid of any
obvious cytotoxicity on macrophage host cells, because the cyto-
toxic concentration causing 50% cell death was 100 g/ml (data
not shown).
It is now known that the major antileishmanial oxidant produced
by activated macrophages is NO, which is most relevant to killing
established intracellular amastigotes (34). We demonstrated that
macrophages pretreated with 20 M GRA produced maximal NO
production and iNOS transcription, which paralleled with maximal
stimulation of leishmaniacidal activity. The exact molecular mech-
anism through which this radical promotes intracellular killing of
FIGURE 7. Nuclear translocation
of p65 and phosphorylation and sub-
sequent degradation of IB in
GRA-treated RAW 264.7 cells. Nor-
mal and infected cells were incubated
in the presence or the absence of
GRA (20 M) for the indicated time
periods at 37°C before preparing cy-
tosolic and nuclear protein extracts
for Western blot analysis. Bands re-
acting with primary Abs against p65
(A) phosphorylated IB (B), and
IB (C) were visualized by ECL.
The blots were analyzed densito-
metrically, and the values were nor-
malized to -actin. The relative val-
ues in terms of fold changes are
indicated. Similar results were ob-
tained in two additional independent
experiments.
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Leishmania is not yet fully defined. However, it may be mentioned
that NO also inhibits Leishmania cysteine proteinase activity, a
known virulence factor, leading to lethal metabolic inhibition
through irreversible chemical modification of reactive cysteine res-
idues (35) as well as blocking the differentiation process from
amastigotes to promastigotes (36). These observations are indica-
tive of the essential role of reactive nitrogen intermediates in the
control of intracellular parasites by murine macrophages, exerting
lytic effects on both parasite developmental stages.
Polarization of Th responses to either Th1 or Th2 can lead to life
or death outcomes to Leishmania infections in mice (37). A grow-
ing body of evidence supports the host protective role of IL-12-
induced differentiation of Th1 cells that produce IFN-, which
activates macrophages to produce NO (38). The acquired resis-
tance to L. donovani infection by GRA therapy may be attributed
to the switch of CD4 T cell-mediated immune responses from
disease-promoting Th2 type to disease-resolving Th1 type, as eval-
uated by the mRNA levels of various cytokines in spleen cells at
different time points after infection. Transcript levels of IL-10 and
IL-4 were reduced in mice given GRA therapy, whereas those for
IL-12 p40 and IFN- were significantly elevated. GRA also in-
creased the levels of TNF-, another inflammatory cytokine with
well-defined antileishmanial effects that is known to act either
alone or with IFN- to induce the production of reactive nitrogen
and oxygen intermediates (39, 40). This type of an intervening, T
cell-dependent mechanism is also reported to be required for op-
timal in vivo responsiveness to pentavalent antimony, the conven-
tional chemotherapeutic agent for leishmaniasis (41). The secre-
tion of the tested cytokine proteins was determined by ELISA.
Although the results obtained by ELISA are in line with the find-
ings using RT-PCR, it seems that the semiquantitative RT-PCR
technique is more sensitive than ELISA.
There is increasing evidence that NF-B family members play
complex regulatory roles in controlling innate and adaptive re-
sponses after infection with Leishmania. Chronic infection in NF-
B2 (p52)/ mice is associated with defective CD40-induced
IL-12 responses, whereas susceptibility to infection in c-Rel/
mice has been attributed to defective NO production and parasite
killing (42, 43). In contrast, susceptibility to infection in NF-B1
(p50)/ mice exhibited a marked defect in the expansion of Ag-
specific CD4 T cells secreting IFN-, underlying its role in the
adaptive immune response (44). Very recently, p50/c-Rel het-
erodimer in monocytes has been found to be selectively induced by
L. major, resulting in production of IL-10 (45). All these findings
suggest the importance of need-based use of various NF-B com-
ponents for fine-tuning gene activation in response to external
stimuli. Our present study has demonstrated that the transcriptional
effects of GRA on genes regulating the expression of iNOS and
Th1 cytokines might result in part from increased translocation of
NF-B into the nucleus of activated cells. GRA has been found to
induce the complex composed of p50/p65 heterodimer in normal
as well as L. donovani-infected macrophages. This observation is
consistent with the recent report that infection by L. major amas-
tigotes blocked nuclear translocation of a PMA-induced p50/p65
NF-B complex in U937 cells (45). Induction of NF-B was ac-
counted for by the transient change as well as phosphorylation of
IB by the IKK multiprotein complex, followed by ubiquitina-
tion and degradation by the 26S proteasome complex (46). The
results of the present study suggest that the kinase activity of IKK
was stimulated in cells that were activated in the presence of GRA
through a mechanism that most likely involves upstream signaling
pathways. This is substantiated by the lack of effect of GRA on
IKK activity when GRA was added directly to the assay mixture
containing IKK immunoprecipitated from normal macrophages.
Although it is possible that GRA interferes with the regulatory
interaction between NF-B essential modifiers (IKK and IKK)
(47), it seems more likely that GRA interferes with one of the key
upstream kinases in the signaling pathway, e.g., NF-B-inducing
kinase, PI3K, or MAPK (48).
In macrophages, the MAPK cascade and the NF-B pathway
play important roles in the regulation of functions involved in in-
flammation and host defense. Previous reports demonstrated that in
naive macrophages, L. donovani promastigotes evade the action of
these pathways and thereby successfully avoid activating macro-
phages for the production of NO and proinflammatory cytokines
(16). Thus, the agents that lead to activation of NF-B pathway
might prove attractive candidates to control infection with Leish-
mania. GRA, a triterpenoid isolated from the root of the licorice
plant, is one such pharmacologically safe compound with known
immunomodulatory properties. However, the development of new
drugs that induce NF-B activation at various points of the signal
transduction pathway will require pharmacokinetic and toxicity
studies in addition to clinical verification of in vivo activity. GRA
has the advantage of being a relatively nontoxic compound. The
pharmacological safety of GRA has been demonstrated by non-
toxic consumption of up to 1.5 g/day in humans (49). Thus, the
marked sensitivity of the macrophage effector responses of NO and
proinflammatory cytokines to GRA suggest that this natural prod-
uct could be used as a potential immunomodulator to generate the
required immunity not only for the treatment of nonhealing leish-
maniasis, but also for the treatment of other chronic infectious
diseases.
FIGURE 8. GRA-induced activation of IKK in RAW 264.7 cells. A,
Normal and infected cells were incubated in the presence or the absence of
GRA for 1 h at 37°C. Whole cell extracts were prepared and immunopre-
cipitated with Abs against IKK and IKK. The activity of immunopre-
cipitated IKK was measured using GST-IB as substrate, and GST-phos-
phorylated IB was visualized by autoradiography. Relative amounts of
IKK and IKK in the whole cell extracts were determined by Western
blots. B, Whole cell extracts were prepared from normal and infected mac-
rophages, and IKK was immunoprecipitated with Abs against IKK and
IKK. The immune complex was treated with GRA (20 M) for 30 min
at 30°C. Unactivated cells served as a control. IKK activity was assessed
using GST-IB as described in A. Equal protein loading was evaluated by
-actin. Similar results were obtained in three additional independent
experiments.
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